Primary and secondary outcomes
| Outcomes | Placebo n=47 (53%) | Ibuprofen n=42 (47%) | Differences % (95% CI) | p Value | Differences OR (95% CI) |
| Acute kidney injury incidence (%) | 16 (34%) | 22 (52%) | 18 (−4% to 41%) | 0.13 | 2.1 (0.9 to 5.1) |
| Risk (%) | 12 (25.5) | 16 (38.1) | 12.6 (−8.9% to 34.1%)%) | 0.3 | 1.8 (0.7 to 4.5) |
| Injury (%) | 4 (8.5) | 6 (14.3) | 5.8 (−9.7% to 21.3%)%) | 0.6 | 1.8 (0.5 to 7.7) |
| Exercise-associated hyponatremia (%) | 7 (7.3) | 3 (14.8) | 7.5 (−22.8% to 7.6%)%) | 0.4 | 0.6 (0.1 to 2.3) |
| Borg (mean, SD) | 15.96 (2.6) | 15.99 (2.5) | 0.1 (1% to 1.1%) | 1 | − |